FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and can be used in treating breast cancer. Disclosed methods involve administering an eribulin and a second agent selected from capecitabine, an antimitotic agent, an antitumour agent based on platinum, doxorubicin and Ixabepilone. Erubulin is administered to subject 1, 2, 3, 4, 5 or 6 days or 1–12 weeks before the said second agent. Kit according to the invention contains eribulin and a second agent.
EFFECT: use of inventions enables improving the anticancer effect ensured by the synergetic effect of the combination.
58 cl, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| METHODS OF TREATING SOLID TUMORS | 2017 |
|
RU2737934C2 |
| USING ERIBULIN FOR TREATING BREAST CANCER | 2013 |
|
RU2689977C2 |
| TREATING THREE RECEPTOR NEGATIVE BREAST CANCER | 2007 |
|
RU2448697C2 |
| USE OF THE PLINABULIN IN COMBINATION WITH THE IMMUNE RESPONSE CONTROL POINT INHIBITORS | 2016 |
|
RU2723021C2 |
| TREATMENT OF PANCREATIC CANCER | 2018 |
|
RU2792690C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| METHODS OF TREATMENT | 2020 |
|
RU2822394C1 |
